Cyclin-dependent kinase 4/6 inhibitors palbociclib or ribociclib combined with endocrine therapy and radiation therapy for patients with metastatic breast cancer

被引：0
|
作者：
Ratosa, I. [1 ]
Scoccimarro, E. [2 ,3 ]
Dominici, L. [2 ,3 ]
Orazem, M. [1 ]
Steinacher, M. [4 ]
Aquilano, M. [2 ,3 ]
Cerbai, C. [2 ,3 ]
Desideri, I. [2 ,3 ]
Marinko, T. [1 ]
Livi, L. [2 ,3 ]
Meattini, I. [2 ,3 ]
机构：
[1] Inst Oncol, Div Radiat Oncol, Ljubljana, Slovenia
[2] Univ Florence, Dept Expt & Clin Biomed Sci M Serio, Florence, Italy
[3] Azienda Osped Univ Careggi, Radiat Oncol Unit, Dept Oncol, Florence, Italy
[4] Univ Med Ctr Maribor, Dept Oncol, Maribor, Slovenia
来源：
EUROPEAN JOURNAL OF CANCER | 2020年 / 138卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
262
引用
收藏
页码：S66 / S66
页数：1
相关论文
共 50 条
  • [41] Overall survival with cyclin-dependent kinase 4/6 inhibitors plus endocrine therapy in breast cancer: A meta-analysis of randomized controlled trials
    Tian, Q.
    Yang, J.
    ANNALS OF ONCOLOGY, 2020, 31 : S366 - S366
  • [42] Cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) plus endocrine therapy (ET) treatment in metastatic lobular breast cancer (mLBC): A retrospective cohort study
    von Arx, C.
    Calabrese, A.
    Martinelli, C.
    Di Lauro, V.
    Grimaldi, V.
    Pensabene, M.
    Caputo, R.
    Cerillo, I.
    Cianniello, D.
    Buono, G.
    Verrazzo, A.
    Pacilio, C.
    Di Rella, F.
    Nuzzo, F.
    De laurentiis, M.
    ANNALS OF ONCOLOGY, 2023, 34 : S370 - S370
  • [43] Integration of Postoperative Radiation Therapy with Cyclin-Dependent Kinase (CDK) Inhibitors
    Fernanda Hayashida Yoshimoto
    Cecilia Félix Penido Mendes de Sousa
    Gustavo Nader Marta
    Samir Abdallah Hanna
    Current Oncology Reports, 2023, 25 : 1153 - 1159
  • [44] Integration of Postoperative Radiation Therapy with Cyclin-Dependent Kinase (CDK) Inhibitors
    Yoshimoto, Fernanda Hayashida
    de Sousa, Cecilia Felix Penido Mendes
    Marta, Gustavo Nader
    Hanna, Samir Abdallah
    CURRENT ONCOLOGY REPORTS, 2023, 25 (10) : 1153 - 1159
  • [45] Timing of Dose Reductions and Survival Outcomes in Metastatic Breast Cancer Patients Treated with Cyclin-Dependent Kinase 4/6 Inhibitors
    Kubilay Tolunay, Pinar
    Kurt Inci, Bediz
    Usta, Sura
    Topkac, Ali
    Karabuga, Berkan
    Aydemir, Ergin
    Oner, Irem
    Akay Hacan, Busra
    Ates, Ozturk
    Karacin, Cengiz
    Yalcintas Arslan, Ulku
    CURRENT ONCOLOGY, 2024, 31 (12) : 7426 - 7436
  • [46] Cyclin-dependent kinase 4/6 inhibitors for cancer therapy: a patent review (2015-2019)
    Wang, Peng-Fei
    Qiu, Han-Yue
    He, Yun
    Zhu, Hai-Liang
    EXPERT OPINION ON THERAPEUTIC PATENTS, 2020, 30 (10) : 795 - 805
  • [47] Incidence and severity of neutropenia in patients treated with cyclin-dependent kinase 4/6 inhibitors (CDKi) for metastatic breast cancer.
    Singh, Anmol
    Giordano, Sharon H.
    Zhang, Ning
    Mac Gregor, Mariana Chavez
    Zhao, Hui
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [48] Clinical outcome and toxicity data in patients with advanced breast cancer treated with cyclin-dependent kinase 4/6 (CDK4/6) inhibitors combined with endocrine therapy in a real-world clinical setting
    Fountzilas, E.
    Koliou, G. -A.
    Rapti, V.
    Nikolakopoulos, A.
    Christopoulou, A.
    Moirogiorgou, E.
    Binas, I.
    Aravantinos, G.
    Kostadima, L.
    Nikolaidi, A.
    Karteri, S.
    Zagouri, F.
    Saridaki, Z.
    Molfeta, A.
    Oikonomopoulou, P.
    Res, E.
    Tryfonopoulos, D.
    Koumakis, G.
    Fountzilas, G.
    Razis, E.
    ANNALS OF ONCOLOGY, 2019, 30
  • [49] Cyclin-dependent kinase 4/6 inhibitor in combination with endocrine therapy versus endocrine therapy only for advanced breast cancer: a systematic review and meta-analysis
    Xu, Zhi-Hong
    Zhang, Heng
    Wei, Deng-Hui
    Xie, Li-Li
    Xu, Chun-Sen
    TRANSLATIONAL CANCER RESEARCH, 2020, 9 (02) : 657 - 668
  • [50] Meta-analysis of cyclin-dependent kinase (CDK) 4/6 inhibitors with endocrine therapy versus endocrine therapy alone on progression-free survival (PFS) and overall survival (OS) for metastatic breast cancer (MBC).
    Kunwor, Ranju
    Baniya, Ramkaji
    Abu-Khalaf, Maysa M.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
12345